<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03347916</url>
  </required_header>
  <id_info>
    <org_study_id>kuwaiteyecenter01</org_study_id>
    <nct_id>NCT03347916</nct_id>
  </id_info>
  <brief_title>Gabapentin Oral Solution in Decreasing Desflurane Associated Emergence Agitation</brief_title>
  <official_title>The Role of Gabapentin Oral Solution in Decreasing Desflurane Associated Emergence Agitation and Delirium in Children After Strabismus Surgery: A Prospective Randomized Double-blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kuwait Specialized Eye Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kuwait Specialized Eye Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      to study the effect of oral gabapentin (5 mg/kg) on emergence agitation after desflurane
      anesthesia in pediatrics undergoing starbismus surgery
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 5, 2017</start_date>
  <completion_date type="Anticipated">November 30, 2017</completion_date>
  <primary_completion_date type="Anticipated">November 25, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>emergence agitation incidence and scores</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>agitation measured by emergence agitation scale: [1= Obtunded with no response to stimuli; 2= Asleep, but responsive to movement and stimuli; 3= Awake and appropriately responsive; and 4= Crying and difficult to console; 5= Wild thrashing behaviour that requires restraint]. A score 4 or 5 was considered as agitation and was treated by IV meperidine 0.5 -1 mg/kg increments.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of emergence</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The time from the discontinuation of anesthesia till the time of spontaneous eye opening or to verbal command</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Emergence Agitation After Desflurane Anesthesia</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients received strawberry juice 5 ml volume, one hour before induction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gabapentin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients received gabapentin (Neurontin oral solution 250 mg/ml, Pfizer, USA) 5 mg/kg mixed with strawberry juice to constitute 5 ml volume, one hour before induction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Strawberry juice as (placebo)</intervention_name>
    <description>Patients received strawberry juice 5 ml volume, one hour before induction.</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Strawberry juice</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin Oral Solution [Neurontin]</intervention_name>
    <description>Patients received gabapentin (Neurontin oral solution 250 mg/ml, Pfizer, USA) 5 mg/kg mixed with strawberry juice to constitute 5 ml volume, one hour before induction.</description>
    <arm_group_label>Gabapentin group</arm_group_label>
    <other_name>Neurontin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pediatric patients (2-6 years old), with an American society of Anesthegiologists
             physical status (ASA) I-II who were undergoing strabismus surgery (for more than one
             muscle)

        Exclusion Criteria:

          -  failure to obtain consent, mental retardation or developmental delay, epilepsy,
             psychiatric or neurological diseases that impair communication, current use of
             gabapentin, psychotropic or opioids.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahmed A. BAdawy, MD</last_name>
    <phone>+96597700293</phone>
    <email>dr.ahmedbadawy545@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicolas Abou Chaar, MsSc</last_name>
    <phone>+96597714558</phone>
    <email>nicolas.abouchaar@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kuwait Specialized Eye Center</name>
      <address>
        <city>Kuwait</city>
        <zip>113111</zip>
        <country>Kuwait</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Abou chaar, MSSc</last_name>
      <phone>+96597714558</phone>
      <email>nicolas.abouchaar@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Kuwait</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2017</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kuwait Specialized Eye Center</investigator_affiliation>
    <investigator_full_name>Ahmed A. Badawy</investigator_full_name>
    <investigator_title>Anesthesia Consultant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Emergence Delirium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Desflurane</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

